LAUREN GRUENSCHLAEGER: Open Payments
NPI 1972218857 · DANVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$289 in 17 payments from 10 companies in 2025. Trend: 2023 $313 · 2024 $574 · 2025 $289
Food & beverage: $289
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 4 | $59 |
| ABBVIE INC. | 3 | $49 |
| Gilead Sciences, Inc. | 2 | $39 |
| Novo Nordisk Inc | 2 | $35 |
| Merck Sharp & Dohme LLC | 1 | $23 |
| PFIZER INC. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| SANOFI-AVENTIS U.S. LLC | 1 | $15 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $14 |
Products named: MOUNJARO, VRAYLAR, VERQUVO, PREVNAR 20, Ozempic, Auvelity, GEMTESA, TZIELD.
Industry payments across KY — which companies pay providers there.
